20
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Policy Endorsement and Booster Shot: Exploring Politicized Determinants for Acceptance of a Third Dose of COVID-19 Vaccine in China

      , , , , ,
      Vaccines
      MDPI AG

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          China’s recent termination of strict COVID-19 control necessitates taking a booster vaccine shot as a precaution against the pandemic as quickly as possible. A large body of research has examined people’s attitudes toward and intentions for the booster shot. However, most studies failed to explore how China’s sociopolitical context has shaped their attitude regarding the booster jab take-up. The current study utilizes data from a national survey adopting quota sampling to analyze the Chinese public’s medical and non-medical considerations to determine their intention for the third dose of the COVID-19 vaccine. The study found that thanks to China’s initial successful lockdown policies, personal risk and benefit perceptions did not dominate their views regarding booster vaccination. Instead, respondents’ gender, nationalism, endorsement of the zero-COVID policy, self-efficacy regarding vaccination, and perceived infection severity were the major factors underlying their booster shot intention. The situation highlights how the politicized context of China’s COVID-19 control has impacted people’s plans to practice preventive behaviors. It is necessary to offset the negative consequences. One strategy is to educate the Chinese public with more medically relevant information to help them make rational choices regarding vaccination and other protective measures. On the other hand, such education can utilize this nationalistic mental status to enhance the persuasion effect.

          Related collections

          Most cited references44

          • Record: found
          • Abstract: found
          • Article: not found

          The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay

          The development of a vaccine against SARS-CoV-2 infection is on the way. To prepare for public availability, the acceptability of a hypothetical COVID-19 vaccine and willingness to pay (WTP) were assessed to provide insights into future demand forecasts and pricing considerations.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Understanding Conspiracy Theories

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England

              Booster vaccination with messenger RNA (mRNA) vaccines has been offered to adults in England starting on 14 September 2021. We used a test-negative case–control design to estimate the relative effectiveness of a booster dose of BNT162b2 (Pfizer-BioNTech) compared to only a two-dose primary course (at least 175 days after the second dose) or unvaccinated individuals from 13 September 2021 to 5 December 2021, when Delta variant was dominant in circulation. Outcomes were symptomatic coronavirus disease 2019 (COVID-19) and hospitalization. The relative effectiveness against symptomatic disease 14–34 days after a BNT162b2 or mRNA-1273 (Moderna) booster after a ChAdOx1-S (AstraZeneca) and BNT162b2 as a primary course ranged from around 85% to 95%. Absolute vaccine effectiveness ranged from 94% to 97% and was similar in all age groups. Limited waning was seen 10 or more weeks after the booster. Against hospitalization or death, absolute effectiveness of a BNT162b2 booster ranged from around 97% to 99% in all age groups irrespective of the primary course, with no evidence of waning up to 10 weeks. This study provides real-world evidence of substantially increased protection from the booster vaccine dose against mild and severe disease irrespective of the primary course. A test-negative case–control analysis of data from the National Immunisation Management System in England demonstrates significant levels of increased protection against hospitalization or death from COVID with mRNA booster vaccines following a primary two-dose course of either ChAdOx1-S or BNT162b2 vaccines.
                Bookmark

                Author and article information

                Contributors
                Journal
                VBSABP
                Vaccines
                Vaccines
                MDPI AG
                2076-393X
                February 2023
                February 12 2023
                : 11
                : 2
                : 421
                Article
                10.3390/vaccines11020421
                36851298
                7ed79ba3-a0ef-4f3b-ad86-c35cc9ef78fe
                © 2023

                https://creativecommons.org/licenses/by/4.0/

                History

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content168

                Cited by3

                Most referenced authors583